882 related articles for article (PubMed ID: 33382908)
1. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
3. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
Shi YK; Wang L; Han BH; Li W; Yu P; Liu YP; Ding CM; Song X; Ma ZY; Ren XL; Feng JF; Zhang HL; Chen GY; Han XH; Wu N; Yao C; Song Y; Zhang SC; Song W; Liu XQ; Zhao SJ; Lin YC; Ye XQ; Li K; Shu YQ; Ding LM; Tan FL; Sun Y
Ann Oncol; 2017 Oct; 28(10):2443-2450. PubMed ID: 28945850
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
[TBL] [Abstract][Full Text] [Related]
5. Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours.
Yue-Yun C; Ye H; Yang F; Qing L; Pan-Pan L; Zhen-Yu D
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2415-2420. PubMed ID: 31450915
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
Wang Y; Yuan X; Yang M; Shen Z; Chen H; He X; Ma Y; Ding L
Pharmacology; 2021; 106(11-12):658-666. PubMed ID: 34673645
[TBL] [Abstract][Full Text] [Related]
7. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study.
Xu L; Qi Q; Zhang Y; Cui J; Liu R; Li Y
Lung Cancer; 2019 Jul; 133():23-31. PubMed ID: 31200823
[TBL] [Abstract][Full Text] [Related]
8. EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study.
Chang Q; Xu J; Qiang H; Teng J; Qian J; Lv M; Zhang Y; Lou Y; Zhao Y; Zhong R; Han B; Chu T
Clin Lung Cancer; 2021 May; 22(3):e395-e404. PubMed ID: 32747190
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Lu S; Ye M; Ding L; Tan F; Fu J; Wu B
Oncotarget; 2017 Feb; 8(6):9996-10006. PubMed ID: 28036283
[TBL] [Abstract][Full Text] [Related]
10. Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.
Feng S; Wang Y; Cai K; Wu H; Xiong G; Wang H; Zhang Z
PLoS One; 2015; 10(10):e0140794. PubMed ID: 26474174
[TBL] [Abstract][Full Text] [Related]
11. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
Song Z; Yu X; Cai J; Shao L; Lin B; He C; Zhang B; Zhang Y
Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):138-43. PubMed ID: 23514942
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
Hosomi Y; Morita S; Sugawara S; Kato T; Fukuhara T; Gemma A; Takahashi K; Fujita Y; Harada T; Minato K; Takamura K; Hagiwara K; Kobayashi K; Nukiwa T; Inoue A;
J Clin Oncol; 2020 Jan; 38(2):115-123. PubMed ID: 31682542
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Masuda T; Imai H; Kuwako T; Miura Y; Yoshino R; Kaira K; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Clin Transl Oncol; 2015 Sep; 17(9):702-9. PubMed ID: 25990507
[TBL] [Abstract][Full Text] [Related]
16. Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.
Jiang Z; Zhang J; Sun H; Wang C; Zhang Y; Li Y; Pan Z
Thorac Cancer; 2021 Sep; 12(17):2369-2374. PubMed ID: 34255422
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report.
Xu T; Wu H; Jin S; Min H; Zhang Z; Shu Y; Wen W; Guo R
Medicine (Baltimore); 2017 Aug; 96(33):e7732. PubMed ID: 28816950
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
Uchibori K; Satouchi M; Sueoka-Aragane N; Urata Y; Sato A; Imamura F; Inoue T; Tachihara M; Kobayashi K; Katakami N; Kokan C; Hirashima T; Iwanaga K; Mori M; Aoe K; Morita S; Negoro S
Lung Cancer; 2018 Oct; 124():65-70. PubMed ID: 30268482
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of the Efficacy and Safety of Icotinib with Standard Second-line
Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer].
Yao S; Qian K; Wang R; Li Y; Zhang Y
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):369-73. PubMed ID: 26104894
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting.
Wang Q; Gao W; Gao F; Jin S; Qu T; Lin F; Zhang C; Zhang J; Zhang Z; Chen L; Guo R
BMC Cancer; 2021 May; 21(1):602. PubMed ID: 34034713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]